Comerica Bank Sells 50,262 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Comerica Bank decreased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 65.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,637 shares of the biopharmaceutical company’s stock after selling 50,262 shares during the period. Comerica Bank’s holdings in Catalyst Pharmaceuticals were worth $622,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Rothschild Investment LLC increased its position in shares of Catalyst Pharmaceuticals by 1,085.7% during the third quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,520 shares in the last quarter. Advisory Services Network LLC bought a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth $39,000. Quarry LP bought a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth $40,000. Financial Life Planners bought a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth $42,000. Finally, First Horizon Corp bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $52,000. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on CPRX. Robert W. Baird downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Truist Financial raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Citigroup downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $35.00 to $31.50 in a research report on Friday. Three research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $32.17.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX opened at $31.15 on Tuesday. The firm has a 50-day moving average of $25.56 and a 200-day moving average of $24.07. Catalyst Pharmaceuticals, Inc. has a one year low of $19.05 and a one year high of $32.56. The company has a market cap of $3.81 billion, a PE ratio of 18.43, a price-to-earnings-growth ratio of 0.95 and a beta of 0.72.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).